Unravelling the Role of Lipoxin A4 in Rotenone Induced Parkinson’s Disease in Experimental Male Albino Rats

The second most prevalent age-related neurodegenerative illness is Parkinson's disease (PD). The purpose of our study was to examine how lipoxin A4 contributes to rotenone-induced Parkinson's disease in male albino experimental rats. Three equal groups of thirty male rats were created: Control I, Rotenone-treated Group II, and Lipoxin A4-treated Group III. Finally, tests of rats' locomotor activity, forced swimming, and elevated T maze were performed. A colorimetric technique was utilized to assess the biomarkers of oxidative stress (MDA and GPX). Furthermore, measurements were made of the inflammatory markers TNFα, IL6, and INOS. In addition, PPAR gamma receptor was measured. Group III that received lipoxin exhibited a significant improvement in motor tests, a drop in inflammatory markers (TNFα, IL6, and INOS) and oxidative stress markers (MDA), and a significant rise in antioxidant GPX levels. Additionally, our results indicated a significant increase in PPAR gamma receptor.Therefore, Lipoxin A4 can be considered to be used as a treatment for parkinsonism. Abbreviations: PD, Parkinson’s disease; MDA, Malondialdehyde; GPX, Glutathione Peroxidase; TNFα, Tumor necrosis factor α; IL6, Interleukin-6; INOS, Inducible nitric oxide synthase; PPAR gamma, peroxisome proliferator-activated receptor gamma gene.